Literature DB >> 18545158

Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation.

Jean-Marie Zimmer1, François Roman, Christine Lambert, Abel Jonckheer, Ana Vazquez, Jean-Marc Plesséria, Jean-Yves Servais, Kris Covens, Jan Weber, Kristel Van Laethem, Jean-Claude Schmit, Anne-Mieke Vandamme, Miguel E Quinones-Mateu, Marc De Maeyer.   

Abstract

We observed an unusual glycine-to-glutamate substitution at protease (PR) residue position 48 (G48E) in an African patient infected with a subtype A1 HIV-1 strain failing a saquinavir-containing regimen. Phenotypic analysis of protease inhibitor (PI) susceptibility showed that the G48E site-directed mutant, when introduced into an NL4-3 HIV-1 PR backbone, was slightly resistant to SQV (2-fold when compared with the wild-type virus). In addition, the G48E and G48E/V82A site-directed mutants were associated with a decrease in fitness, whereas a reversion to the wild type at position 48 was observed in vitro. Growth competition experiments using a novel growth competition assay based on enhanced green fluorescent protein- or Discosoma spp. red fluorescent protein-expressing viruses showed that the replicative fitness of the G48E virus was reduced to 55% compared with the parental NL4-3 virus. Synthesizing all possible site-directed mutants found in the patient strain is too time-consuming; therefore, a molecular dynamics (MD) simulation approach was used to understand why this mutation survived despite its fitness cost. These simulations documented that the G48E mutant interacted with PI resistance mutations (M46I, I54V, Q58E, and L63P) and with natural polymorphisms specific to subtype A1 (E35D, M36I, and R57K) that were present in the patient's virus. We hypothesize that the polymorphisms contained in the PR flap regions of the patient's virus may compensate for the presence of G48E, possibly by restoring the flexibility of the PR flaps. In summary, our results demonstrate that the G48E substitution, when introduced in the context of an HIV-1 subtype B strain, is highly unstable and gives rise to viruses with a poor replicative fitness in vitro. We also showed that when confronted with too many mutations to evaluate in vitro, MD simulations are helpful to draft hypotheses on how polymorphisms can interact with resistance mutations to stabilize their potential fitness cost.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18545158     DOI: 10.1097/QAI.0b013e318174dca6

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

1.  Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Authors:  Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Differential persistence of transmitted HIV-1 drug resistance mutation classes.

Authors:  Vivek Jain; Maria C Sucupira; Peter Bacchetti; Wendy Hartogensis; Ricardo S Diaz; Esper G Kallas; Luiz M Janini; Teri Liegler; Christopher D Pilcher; Robert M Grant; Rodrigo Cortes; Steven G Deeks; Frederick M Hecht
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

3.  The impact of wild-type reversion on transmitted resistance surveillance.

Authors:  David C Boettiger; Sasisopin Kiertiburanakul; Somnuek Sungkanuparph; Matthew G Law
Journal:  Antivir Ther       Date:  2014-02-17

4.  HIV-1 protease inhibitor drug resistance in Kenyan antiretroviral treatment-naive and -experienced injection drug users and non-drug users.

Authors:  Valentine Budambula; Francis O Musumba; Mark K Webale; Titus M Kahiga; Francisca Ongecha-Owuor; James N Kiarie; George A Sowayi; Aabid A Ahmed; Collins Ouma; Tom Were
Journal:  AIDS Res Ther       Date:  2015-08-15       Impact factor: 2.250

5.  Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.

Authors:  Szu-Wei Huang; Wei-You Li; Wen-Hung Wang; Yu-Ting Lin; Chih-Hung Chou; Marcelo Chen; Hsien-Da Huang; Yen-Hsu Chen; Po-Liang Lu; Sheng-Fan Wang; Shinichi Oka; Yi-Ming Arthur Chen
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.